Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE006 (GBR) (Dr. Rossi)
· consented 2022-09-01
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-18 (study day 4); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 7); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 56); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 367); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 400); relationship: N
severe
serious
assessed
2026-08-18
Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-14 (study day 426); relationship: N; serious criteria: life-threatening
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.